<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076530</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02011</org_study_id>
    <secondary_id>ADVL0819</secondary_id>
    <secondary_id>CDR0000664388</secondary_id>
    <secondary_id>COG-ADVL0819</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <nct_id>NCT01076530</nct_id>
  </id_info>
  <brief_title>Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors</brief_title>
  <official_title>A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of vorinostat when given&#xD;
      together with temozolomide in treating young patients with relapsed or refractory primary&#xD;
      brain tumors or spinal cord tumors. Vorinostat may stop the growth of tumor cells by blocking&#xD;
      some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Vorinostat may help temozolomide work better by making tumor&#xD;
      cells more sensitive to the drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the maximum tolerated dose and/or recommended phase II dose of vorinostat in&#xD;
      combination with temozolomide in pediatric patients with relapsed or refractory primary CNS&#xD;
      tumors.&#xD;
&#xD;
      II. To define and describe the toxicities of this regimen in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To preliminarily define the antitumor activity of this regimen within the confines of a&#xD;
      phase I study.&#xD;
&#xD;
      II. To characterize the pharmacokinetic parameters of vorinostat in these patients.&#xD;
&#xD;
      III. To determine whether acetylated histones in peripheral blood mononuclear cells can be&#xD;
      identified as a surrogate marker of the biologic effect of vorinostat at various treatment&#xD;
      doses.&#xD;
&#xD;
      IV. To assess the feasibility of collecting and analyzing serum DNA for methylation of the&#xD;
      MGMT promoter and describe the relationship between promoter methylation and clinical&#xD;
      responses within the confines of this phase I study.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of vorinostat.&#xD;
&#xD;
      Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat&#xD;
      every 28 days for up to 13 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients may undergo blood sample collection periodically for pharmacokinetic and correlative&#xD;
      laboratory studies by western blotting and MGMT promoter methylation assays.&#xD;
&#xD;
      After completion of study therapy, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose defined as the maximum dose at which fewer than one-third of patients experience DLT using NCI CTCAE version 4.0</measure>
    <time_frame>28 days</time_frame>
    <description>In addition to determination of the MTD, a descriptive summary of all toxicities will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of vorinostat in combination with temozolomide</measure>
    <time_frame>Pre-dose, 15 and 30 minutes, 1, 2, 4, 6, 8, and 24 hours</time_frame>
    <description>The PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response assessed according to RECIST criteria</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Will be reported descriptively.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Childhood Atypical Teratoid/Rhabdoid Tumor</condition>
  <condition>Childhood Central Nervous System Choriocarcinoma</condition>
  <condition>Childhood Central Nervous System Embryonal Tumor</condition>
  <condition>Childhood Central Nervous System Germinoma</condition>
  <condition>Childhood Central Nervous System Mixed Germ Cell Tumor</condition>
  <condition>Childhood Central Nervous System Teratoma</condition>
  <condition>Childhood Central Nervous System Yolk Sac Tumor</condition>
  <condition>Childhood Choroid Plexus Tumor</condition>
  <condition>Childhood Craniopharyngioma</condition>
  <condition>Childhood Ependymoblastoma</condition>
  <condition>Childhood Grade I Meningioma</condition>
  <condition>Childhood Grade II Meningioma</condition>
  <condition>Childhood Grade III Meningioma</condition>
  <condition>Childhood High-grade Cerebellar Astrocytoma</condition>
  <condition>Childhood High-grade Cerebral Astrocytoma</condition>
  <condition>Childhood Infratentorial Ependymoma</condition>
  <condition>Childhood Low-grade Cerebellar Astrocytoma</condition>
  <condition>Childhood Low-grade Cerebral Astrocytoma</condition>
  <condition>Childhood Medulloepithelioma</condition>
  <condition>Childhood Mixed Glioma</condition>
  <condition>Childhood Oligodendroglioma</condition>
  <condition>Childhood Supratentorial Ependymoma</condition>
  <condition>Extra-adrenal Paraganglioma</condition>
  <condition>Recurrent Childhood Brain Stem Glioma</condition>
  <condition>Recurrent Childhood Central Nervous System Embryonal Tumor</condition>
  <condition>Recurrent Childhood Cerebellar Astrocytoma</condition>
  <condition>Recurrent Childhood Cerebral Astrocytoma</condition>
  <condition>Recurrent Childhood Ependymoma</condition>
  <condition>Recurrent Childhood Medulloblastoma</condition>
  <condition>Recurrent Childhood Pineoblastoma</condition>
  <condition>Recurrent Childhood Spinal Cord Neoplasm</condition>
  <condition>Recurrent Childhood Subependymal Giant Cell Astrocytoma</condition>
  <condition>Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Childhood Visual Pathway and Hypothalamic Glioma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>suberoylanilide hydroxamic acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>SCH 52365</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temodar</other_name>
    <other_name>TMZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed CNS malignancy at original diagnosis or relapse&#xD;
&#xD;
               -  Histologic confirmation not required for patients with intrinsic brain stem&#xD;
                  tumors, optic pathway gliomas, or pineal tumors provided CSF or serum tumor&#xD;
                  markers, including alpha-fetoprotein orbeta-HCG, are elevated&#xD;
&#xD;
               -  Recurrent or refractory spinal cord tumors allowed&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No known curative therapy or therapy proven to prolong survival with an acceptable&#xD;
             quality of life&#xD;
&#xD;
          -  Karnofsky performance status (PS) 50-100% (for patients &gt; 16 years of age) OR Lansky&#xD;
             PS 50-100% (for patients ≤ 16 years of age)&#xD;
&#xD;
               -  Neurological deficits must have been relatively stable for ≥ 1 week before study&#xD;
                  entry&#xD;
&#xD;
               -  Patients unable to walk due to paralysis, but who are up in a wheelchair, are&#xD;
                  considered ambulatory for the purpose of assessing performance status&#xD;
&#xD;
          -  ANC ≥ 1,000/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL (transfusion independent, defined as no platelet&#xD;
             transfusion within the past 7 days)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)&#xD;
&#xD;
          -  Creatinine clearance or radioisotope GFR ≥ 70mL/min OR maximum serum creatinine based&#xD;
             on age and/or gender as follows:&#xD;
&#xD;
               -  0.6 mg/dL (1 year of age)&#xD;
&#xD;
               -  0.8 mg/dL (2 to 5 years of age)&#xD;
&#xD;
               -  1.0 mg/dL (6 to 9 years of age)&#xD;
&#xD;
               -  1.2 mg/dL (10 to 12 years of age)&#xD;
&#xD;
               -  1.5 mg/dL (males) or 1.4 mg/dL (females) (13 to 15 years of age)&#xD;
&#xD;
               -  1.7 mg/dL (males) or 1.4 mg/dL (females) (≥ 16 years of age)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  ALT ≤ 110 U/L&#xD;
&#xD;
          -  Serum albumin ≥ 2 g/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to swallow capsules or liquid&#xD;
&#xD;
          -  Seizure disorder allowed provided it is well controlled with nonenzyme-inducing&#xD;
             anticonvulsants&#xD;
&#xD;
          -  No pre-existing QTc ≥ 450 msec&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No patients who, in the opinion of the investigator, may not be able to comply with&#xD;
             the safety monitoring requirements of study&#xD;
&#xD;
          -  Fully recovered from prior chemotherapy, immunotherapy, or radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)&#xD;
&#xD;
          -  At least 7 days since prior hematopoietic growth factors&#xD;
&#xD;
          -  At least 7 days since prior biologic agent (antineoplastic agent)&#xD;
&#xD;
          -  At least 7 days or 3 half-lives, whichever is longer, since prior monoclonal&#xD;
             antibodies&#xD;
&#xD;
          -  More than 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  At least 6 months since prior total-body radiotherapy (TBI), craniospinal&#xD;
             radiotherapy, or radiotherapy to ≥ 50% of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  At least 3 months since prior stem cell transplantation or rescue (without TBI)&#xD;
&#xD;
               -  No evidence of active graft-vs-host disease&#xD;
&#xD;
          -  At least 2 weeks since prior valproic acid&#xD;
&#xD;
          -  No prior vorinostat&#xD;
&#xD;
          -  Prior temozolomide allowed provided there was no progressive disease during or within&#xD;
             1 month after completion of treatment&#xD;
&#xD;
          -  Concurrent corticosteroids allowed provided patient has been on a stable or decreasing&#xD;
             dose for ≥ 7 days before study entry&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer agents, including chemotherapy, radiotherapy,&#xD;
             immunotherapy, or biologic therapy&#xD;
&#xD;
          -  No concurrent enzyme-inducing anticonvulsants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trent Hummel</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center-Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <last_update_submitted>May 1, 2013</last_update_submitted>
  <last_update_submitted_qc>May 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Teratoma</mesh_term>
    <mesh_term>Endodermal Sinus Tumor</mesh_term>
    <mesh_term>Choriocarcinoma</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Craniopharyngioma</mesh_term>
    <mesh_term>Adamantinoma</mesh_term>
    <mesh_term>Choroid Plexus Neoplasms</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Spinal Cord Neoplasms</mesh_term>
    <mesh_term>Germinoma</mesh_term>
    <mesh_term>Paraganglioma, Extra-Adrenal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

